首页> 外文期刊>Neuroendocrinology: International Journal for Basic and Clinical Studies on Neuroendocrine Relationships >Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1,000 operations.
【24h】

Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1,000 operations.

机译:经蝶窦显微手术用于新诊断的肢端肥大症:经过1000多次手术后的个人观点。

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this short review is to inform about the possibilities and limits of transnasal microsurgery in acromegaly. The current reports on surgical remissions, according to the strict criteria with international consensus using age- and sex-related normal levels for insulin-like growth factor-I and suppression of growth hormone (GH) with oral glucose tolerance below 1 mug/l, are more or less agreeable with values between 34 and 74%. In microadenomas (<10 mm in diameter), 59-95% remissions are published. Some improvement might be achieved in macroadenomas which presently have a chance of 26-68% to be satisfactorily operated on. Special instruments introduced by us to visualize and remove partially invasive adenoma parts are described. Intraoperative magnetic resonance imaging is discussed. With intraoperative measurement of GH, small adenoma rests <3 mm can be diagnosed. When GH did not sufficiently decline, an additional tumor search resulted in a significant improvement in results in resectable macroadenomas. With these techniques, we achieved remission rates which can hardly be further increased (micros 95%, macros 68%). In grossly invasive grade 4 adenomas, which are frequent in our unit, only an 80-95% reduction in tumor mass is feasible. Preoperative treatment with somatostatin analogues as used in most of our patients reduces the comorbidity and facilitates adenoma removal which is still controversially discussed in the literature. The complication rate of microsurgery in experienced hands is low.
机译:这篇简短评论的目的是告知在肢端肥大症中经鼻显微外科手术的可能性和局限性。当前有关外科手术缓解的报告,是根据严格的标准并获得国际共识的,使用与年龄和性别相关的胰岛素样生长因子-I的正常水平并抑制口服葡萄糖耐量低于1杯/升的生长激素(GH),与34%到74%之间的值差不多。在微腺瘤(直径<10 mm)中,有59-95%的缓解率。宏观腺瘤可能会有所改善,目前有26-68%的机会可以满意地手术。描述了我们引入的用于可视化和去除部分浸润性腺瘤部位的特殊仪器。讨论了术中磁共振成像。通过术中GH的测量,可以诊断出<3 mm的小腺瘤。当GH没有充分下降时,额外的肿瘤搜索导致可切除的大腺瘤的结果得到显着改善。通过这些技术,我们实现了几乎无法进一步提高的缓解率(微米95%,宏68%)。在我们单位中常见的严重浸润性4级腺瘤中,仅可将肿瘤量减少80-95%是可行的。在我们大多数患者中使用生长抑素类似物进行术前治疗可降低合并症,并促进腺瘤切除,这在文献中仍存在争议。经验丰富的手中显微外科手术的并发症发生率低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号